Dyne Therapeutics, Inc.

Contributing Author

Recent Articles by Dyne Therapeutics, Inc.

Dec-11	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares DYN GlobeNewswire
Dec-09	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock DYN GlobeNewswire
Dec-08	Dyne Therapeutics Announces Proposed Public Offering of Common Stock DYN GlobeNewswire
Dec-08	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) DYN GlobeNewswire
Dec-07	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET DYN GlobeNewswire
Nov-05	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights DYN GlobeNewswire
Nov-03	Dyne Therapeutics to Present at Upcoming Investor Conferences DYN GlobeNewswire
Oct-06	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) DYN GlobeNewswire
Oct-02	Dyne Therapeutics Appoints Brian Posner to its Board of Directors DYN GlobeNewswire
Sep-29	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy DYN GlobeNewswire
Aug-27	Dyne Therapeutics to Present at Upcoming Investor Conferences DYN GlobeNewswire
Aug-04	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) DYN GlobeNewswire
Jul-28	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights DYN GlobeNewswire
Jul-02	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares DYN GlobeNewswire
Jun-30	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock DYN GlobeNewswire
Jun-30	Dyne Therapeutics Announces Proposed Public Offering of Common Stock DYN GlobeNewswire
Jun-30	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital DYN GlobeNewswire
Jun-17	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting DYN GlobeNewswire
Jun-16	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET DYN GlobeNewswire
Jun-05	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress DYN GlobeNewswire
May-08	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights DYN GlobeNewswire

Dyne Therapeutics, Inc.

Recent Articles by Dyne Therapeutics, Inc.

Upgrade your FINVIZ experience